If we extrapolate the costs incurred from the first 3 quarters...

If we extrapolate the costs incurred from the first 3 quarters this FY, the total for the year will be circa $8.4m.
We know that they got a $1.6m R&D grant refund in FY '23 from the R&D work done in FY '22 and there's no reason to expect that the FY'23 R&D work ($2.06m as at March 1/4 YTD - which is equal to a $1m refund) won't result in a refund as well. For my purposes below I have assumed no further R&D spend & therefore the R&D refund for FY'24 is assumed to be $1m.
That means SPX needs to get other cash receipts to at least $1.85m per quarter to be cashflow positive over the next 12 month period. That's not happening in the June 1/4.
However, given that gap to annualized CF+ was just over $1m in the March 1/4, I think the June 1/4 will have halved the gap between cash receipts and annualized CF+ from the previous 1/4.